PT3428274T - Uso de domínios de proteínas de interação com os nucleossomas para intensificar a modificação visada do genoma - Google Patents

Uso de domínios de proteínas de interação com os nucleossomas para intensificar a modificação visada do genoma

Info

Publication number
PT3428274T
PT3428274T PT181829995T PT18182999T PT3428274T PT 3428274 T PT3428274 T PT 3428274T PT 181829995 T PT181829995 T PT 181829995T PT 18182999 T PT18182999 T PT 18182999T PT 3428274 T PT3428274 T PT 3428274T
Authority
PT
Portugal
Prior art keywords
interacting protein
protein domains
genome modification
targeted genome
enhance targeted
Prior art date
Application number
PT181829995T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Publication of PT3428274T publication Critical patent/PT3428274T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT181829995T 2017-07-11 2018-07-11 Uso de domínios de proteínas de interação com os nucleossomas para intensificar a modificação visada do genoma PT3428274T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531222P 2017-07-11 2017-07-11

Publications (1)

Publication Number Publication Date
PT3428274T true PT3428274T (pt) 2021-11-05

Family

ID=62916578

Family Applications (1)

Application Number Title Priority Date Filing Date
PT181829995T PT3428274T (pt) 2017-07-11 2018-07-11 Uso de domínios de proteínas de interação com os nucleossomas para intensificar a modificação visada do genoma

Country Status (17)

Country Link
US (3) US10604752B2 (ko)
EP (2) EP3988656B1 (ko)
JP (3) JP6994560B2 (ko)
KR (3) KR20240046316A (ko)
CN (1) CN111183226A (ko)
AU (3) AU2018299995B2 (ko)
BR (1) BR112019028261A2 (ko)
CA (1) CA3066790C (ko)
DK (1) DK3428274T3 (ko)
ES (1) ES2901629T3 (ko)
GB (3) GB2567917B (ko)
IL (2) IL271197B2 (ko)
LT (1) LT3428274T (ko)
PL (1) PL3428274T3 (ko)
PT (1) PT3428274T (ko)
SG (1) SG11201911864PA (ko)
WO (1) WO2019014230A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240046316A (ko) 2017-07-11 2024-04-08 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3752607A1 (en) * 2018-02-15 2020-12-23 Sigma Aldrich Co. LLC Engineered cas9 systems for eukaryotic genome modification
WO2019204766A1 (en) 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
WO2020036653A2 (en) * 2018-04-25 2020-02-20 The Regents Of The University Of California Improved method for homology directed repair in cells
WO2020187272A1 (zh) * 2019-03-19 2020-09-24 上海邦耀生物科技有限公司 一种用于基因治疗的融合蛋白及其应用
CN111718418B (zh) * 2019-03-19 2021-08-27 华东师范大学 一种增强基因编辑的融合蛋白及其应用
CN111718420B (zh) * 2019-03-19 2021-09-14 华东师范大学 一种用于基因治疗的融合蛋白及其应用
JP2022533589A (ja) * 2019-05-13 2022-07-25 イーエムディ・ミリポア・コーポレイション Ｃｒｉｓｐｒタンパク質をコードする合成自己複製ｒｎａベクターおよびその使用
WO2021224506A1 (en) * 2020-05-08 2021-11-11 Universitat Pompeu Fabra Crispr-cas homology directed repair enhancer
KR102679001B1 (ko) * 2020-09-21 2024-06-28 고려대학교 산학협력단 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
CN114507689B (zh) * 2022-01-27 2024-01-16 山东大学 一种提高真核生物基因编辑效率的方法及其应用
CN115716880A (zh) * 2022-12-07 2023-02-28 云舟生物科技(广州)股份有限公司 一种核定位荧光蛋白及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003046141A2 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US20130274129A1 (en) 2012-04-04 2013-10-17 Geneart Ag Tal-effector assembly platform, customized services, kits and assays
ES2757623T3 (es) * 2012-07-25 2020-04-29 Broad Inst Inc Proteínas de unión a ADN inducibles y herramientas de perturbación genómica y aplicaciones de las mismas
PL2928496T3 (pl) 2012-12-06 2020-04-30 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu w oparciu o CRISPR
KR102210322B1 (ko) * 2013-03-15 2021-02-01 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US10570418B2 (en) * 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
WO2016049251A1 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10190106B2 (en) * 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
AU2015370435A1 (en) 2014-12-24 2017-06-15 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
ES2886599T3 (es) * 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
EP3313445A1 (en) 2015-06-24 2018-05-02 Sigma Aldrich Co. LLC Cell cycle dependent genome regulation and modification
WO2017031483A1 (en) 2015-08-20 2017-02-23 Applied Stemcell, Inc. Nuclease with enhanced efficiency of genome editing
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
KR20240046316A (ko) 2017-07-11 2024-04-08 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용

Also Published As

Publication number Publication date
AU2021245148A1 (en) 2021-11-04
IL271197B1 (en) 2024-02-01
JP6994560B2 (ja) 2022-02-21
PL3428274T3 (pl) 2022-01-03
US12065642B2 (en) 2024-08-20
CA3066790A1 (en) 2019-01-17
KR20200021529A (ko) 2020-02-28
CA3066790C (en) 2023-07-18
EP3428274B1 (en) 2021-10-13
JP2024096783A (ja) 2024-07-17
JP2020530287A (ja) 2020-10-22
AU2018299995B2 (en) 2021-10-28
KR102655021B1 (ko) 2024-04-04
AU2021245148B2 (en) 2024-01-04
ES2901629T3 (es) 2022-03-23
US20190017042A1 (en) 2019-01-17
US20200208135A1 (en) 2020-07-02
EP3988656A1 (en) 2022-04-27
KR20230053732A (ko) 2023-04-21
KR20240046316A (ko) 2024-04-08
IL309801A (en) 2024-02-01
DK3428274T3 (da) 2021-11-15
JP7469285B2 (ja) 2024-04-16
GB2567917A (en) 2019-05-01
WO2019014230A1 (en) 2019-01-17
IL271197B2 (en) 2024-06-01
GB2598847B (en) 2022-06-01
CN111183226A (zh) 2020-05-19
EP3988656B1 (en) 2024-09-18
AU2022200851A1 (en) 2022-03-03
GB2593814A (en) 2021-10-06
AU2018299995A1 (en) 2020-01-02
GB202103935D0 (en) 2021-05-05
KR102523217B1 (ko) 2023-04-20
AU2022200851B2 (en) 2023-12-14
SG11201911864PA (en) 2020-01-30
EP3428274A1 (en) 2019-01-16
US10604752B2 (en) 2020-03-31
IL309801B1 (en) 2024-08-01
GB2598847A (en) 2022-03-16
IL271197A (en) 2020-01-30
BR112019028261A2 (pt) 2020-07-14
GB2593814B (en) 2022-01-05
GB202114520D0 (en) 2021-11-24
GB201811358D0 (en) 2018-08-29
LT3428274T (lt) 2021-11-25
US20210024916A1 (en) 2021-01-28
GB2567917B (en) 2021-05-12
JP2022046532A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
GB2567917B (en) Using nucleosome interacting protein domains to enhance targeted genome modification
IL295358A (en) Use of programmable DNA-binding proteins to enhance targeted genome modification
IL268894A (en) Medical RNA
HK1247636A1 (zh) Rna指導的人類jc病毒和其他多瘤病毒的根除
HK1249058A1 (zh) 用於增强靶向蛋白質降解的化合物和方法
SG11201707663SA (en) Lyophilization of rna
ZA201805634B (en) Conjugate of therapeutic enzymes
IL290733A (en) Conjugations of quaternary tubulin compounds
IL262419A (en) A therapeutic composition containing enzyme-rich cannabis
GB201711481D0 (en) Protein purification
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
ZA201902689B (en) Therapeutic protein
GB201411506D0 (en) Modified latency associated protein construct
EP3265550C0 (en) SYNERGIC REMOVAL OF PROTEIN SOIL USING A NEW COMBINATION OF CHELATORS
SG10201910999TA (en) Native protein purification technology
GB201622116D0 (en) Treatment of liver disease
GB201704922D0 (en) Methods of protein stapling
GB201712596D0 (en) Improved photobioreactor
GB201616715D0 (en) Therapeutic protein
EP3302067A4 (en) Use of proteins to control molluscs
GB201521541D0 (en) New therapeutic uses of enzyme inhibitors
GB201521547D0 (en) New therapeutic uses of enzyme inhibitors